title: Appropriate and inappropriate use of immunotherapy.
abstract: OBJECTIVE
  The primary objective of this review is to discuss indications for appropriate and inappropriate use of allergen immunotherapy (IT), including discussion of contraindications, adverse events, and alternative protocols and methods.
  
  
  METHODS
  A review of the literature on indications, contraindications, adverse events, and alternative methods and protocols associated with allergen IT was conducted.
  
  
  METHODS
  The opinion of the author was used to select and review relevant data.
  
  
  RESULTS
  Clinical trials have proven the benefit of allergen IT, for allergic rhinitis, asthma, and anaphylaxis because of stinging insects, such as Hymenoptera and fire ants. Allergen IT may improve quality of life and decrease medication requirement for allergic rhinitis and asthma, especially for younger patients, and probably will assist in the prevention of the progression of allergic disease from rhinitis to asthma. Subcutaneous allergen IT is well established as clinically effective through multiple, blinded, placebo-controlled studies. The data for alternate therapies and routes of therapy are extensively reviewed and critiqued.
  
  
  CONCLUSIONS
  Allergen IT is a highly valuable form of treatment of IgE-mediated diseases. Documentation of sensitivity to allergen sensitization associated with symptoms is critical before use of allergen IT. Symptoms should also be of sufficient duration and severity to warrant IT. Before allergen IT is used, there must be an available allergen extract that is suitable for treatment of the relative sensitivity. It is essential for patients receiving allergen IT to understand the treatment principle, the frequency of injections, the duration of treatment, the risk and signs of adverse events, the magnitude of the efficacy, and the essential nature of patient compliance. Subcutaneous allergen IT is the only current mode of therapy in the United States that has been shown to be effective.
authors.forename: L M
authors.initials: LM
authors.lastname: DuBuske
mesh_terms: D006801:Humans; D007167:Immunotherapy / Q000706:statistics & numerical data*